Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
20 December 2021 | Story Igno van Niekerk | Photo Igno van Niekerk
Dr Samantha Potgieter, Senior Lecturer in the Department of Internal Medicine and Dr Nicholas Pearce, Senior Lecturer in the Department of Surgery comment on their team members’ commitment and determination during the pandemic.

On the forefront of the battle against the COVID-19 pandemic, two UFS doctors are leading a team of inspired healthcare workers in a superhuman effort to make a positive difference.

With the pandemic in its second year and the recurring challenges of new waves and strains consistently in the news, one would expect the doctors to be tired. However, quite the opposite is true.  Upon entering the office where Dr Samantha Potgieter, Senior Lecturer in the Department of Internal Medicine and Dr Nicholas Pearce, Senior Lecturer in the Department of Surgery are in a meeting with colleagues, the debate is vibrant; an energetic sense of mission.

Miraculously succeeded

My brief is to collect stories and experiences they’ve had over the past 18 months at the Tumelo ward for general and high-care patients, where the team has miraculously succeeded in not running out of oxygen or ventilators, despite handling high volumes of patients from the Free State and Northern Cape. “We saw those pictures of piled-up bodies in Italy. We were committed to avoiding that at all costs. And we did.”

Success stories? First mentioned are their team members’ commitment and determination. The team had to stand in when families could not support dying patients. “They did not die alone. Our team was there.”  

“Really sad and frustrating are the deaths that could have been prevented. Unvaccinated patients. They arrive ill, wanting to know if they can get it. Too late...” – Dr Nicholas Pearce


Then came hope


Sad stories? The past year has had its share of sad stories. “Someone comes in during the morning, needs oxygen, in the afternoon they are in ICU, then ventilator – and then they die. We’ve never faced anything like this before.”  

Then came hope. Vaccines. Dr Pearce is in charge of the vaccination site at Universitas Hospital. “Really sad and frustrating are the deaths that could have been prevented. Unvaccinated patients. They arrive ill, wanting to know if they can get it. Too late ...” He opens his cell phone – shares the stats. “We can handle 2 000 vaccinations a day. At the moment about 250 comes in.” He shakes his head.  

“We can beat this virus, but we need to stand together ...”

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept